Literature DB >> 15053378

Miltefosine: an oral drug for visceral leishmaniasis.

Rajniti Prasad1, Ranjeet Kumar, B P Jaiswal, Utpal Kant Singh.   

Abstract

Miltefosine, a phosphocholine analogue originally developed as antimalignant drug, has been found to be highly active against leishmania in vitro and animal model. Based on these experiences this drug was tried against human visceral leishmaniasis and found to be highly effective and achieved 97% and 94% cure in phase 2 and phase 3 trial in children.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15053378     DOI： 10.1007/bf02723096

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN： 0019-5456            Impact factor:   1.967


  8 in total

1.  Oral miltefosine for Indian visceral leishmaniasis.

Authors:  Shyam Sundar; T K Jha; C P Thakur; Juergen Engel; Herbert Sindermann; Christina Fischer; Klaus Junge; Anthony Bryceson; Jonathan Berman
Journal:  N Engl J Med       Date:  2002-11-28       Impact factor: 91.245

Review 2.  Epidemiology of visceral leishmaniasis in India.

Authors:  D Bora
Journal:  Natl Med J India       Date:  1999 Mar-Apr       Impact factor: 0.537

3.  Oral miltefosine treatment in children with mild to moderate Indian visceral leishmaniasis.

Authors:  Shyam Sundar; T K Jha; Herbert Sindermann; Klaus Junge; Peter Bachmann; Jonathan Berman
Journal:  Pediatr Infect Dis J       Date:  2003-05       Impact factor: 2.129

4.  Lem3p is essential for the uptake and potency of alkylphosphocholine drugs, edelfosine and miltefosine.

Authors:  Pamela K Hanson; Lynn Malone; Jennifer L Birchmore; J Wylie Nichols
Journal:  J Biol Chem       Date:  2003-07-03       Impact factor: 5.157

5.  Leishmania donovani resistance to miltefosine involves a defective inward translocation of the drug.

Authors:  F Javier Pérez-Victoria; Santiago Castanys; Francisco Gamarro
Journal:  Antimicrob Agents Chemother       Date:  2003-08       Impact factor: 5.191

Review 6.  Membrane targeted anticancer drugs: potent inducers of apoptosis and putative radiosensitisers.

Authors:  V Jendrossek; R Handrick
Journal:  Curr Med Chem Anticancer Agents       Date:  2003-09

7.  Hexadecylphosphocholine: oral treatment of visceral leishmaniasis in mice.

Authors:  A Kuhlencord; T Maniera; H Eibl; C Unger
Journal:  Antimicrob Agents Chemother       Date:  1992-08       Impact factor: 5.191

8.  The activity of alkyl phosphorylcholines and related derivatives against Leishmania donovani.

Authors:  S L Croft; R A Neal; W Pendergast; J H Chan
Journal:  Biochem Pharmacol       Date:  1987-08-15       Impact factor: 5.858
  8 in total
  3 in total

1.  Pharmacokinetics of oral sitamaquine taken with or without food and safety and efficacy for treatment of visceral leishmaniais: a randomized study in Bihar, India.

Authors:  Shyam Sundar; Prabhat K Sinha; Susan A Dixon; Renata Buckley; Ann K Miller; Khadeeja Mohamed; Mahir Al-Banna
Journal:  Am J Trop Med Hyg       Date:  2011-06       Impact factor: 2.345

2.  Miltefosine: First Oral Drug for Treatment of Visceral Leishmaniasis.

Authors:  V K Agrawal; Zile Singh
Journal:  Med J Armed Forces India       Date:  2011-07-21

Review 3.  Persistence and Changing Distribution of Leishmaniases in Kenya Require a Paradigm Shift.

Authors:  Francan F Ouma; Chrispinus S Mulambalah
Journal:  J Parasitol Res       Date:  2021-10-18
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.